[{"data":1,"prerenderedAt":168},["ShallowReactive",2],{"drug-bimatoprost":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":33,"contraindications":56,"warnings":66,"renal":74,"monitoring":75,"interactions":76,"review":77,"examples":80,"atc":86,"iran":88,"usApproval":116,"links":122,"populations":142},"bimatoprost",1,{"fa":7,"en":8},"بیماتوپروست","Bimatoprost","sensory-organs",{"fa":11,"en":12},"آنالوگ پروستاگلاندین (چشمی)","Prostaglandin analogue (ophthalmic)",[14],{"name":15,"market":16},"Lumigan","US",[18,19,7],"lumigan","لومیگان",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":28,"refs":29},"drops","eye-drops","ophthalmic","0.01% (0.1 mg\u002FmL) eye drops",{"amount":5,"unit":27,"perUnit":27},"drop",[16],[30],{"source":31,"section":32},"fda-lumigan","3",[34],{"id":35,"disease":36,"label":37,"population":40,"type":44,"unit":27,"dose":45,"refs":46,"notes":49},"glc","glaucoma",{"fa":38,"en":39},"گلوکوم زاویه باز یا فشار بالای چشم — یک قطره در چشم مبتلا یک بار شب","Open-angle glaucoma or ocular hypertension — 1 drop in the affected eye(s) once nightly",{"minAge":41},{"value":42,"unit":43},18,"year","fixed",{"perDose":5,"dosesPerDay":5},[47],{"source":31,"section":48},"2",[50],{"text":51,"refs":54},{"fa":52,"en":53},"بیش از یک بار در روز اثر را کم می‌کند. با سایر قطره‌ها ۵ دقیقه فاصله.","More than once daily reduces the effect. Separate other drops by 5 min.",[55],{"source":31,"section":48},[57],{"id":58,"severity":59,"text":60,"refs":63},"hyper","block",{"fa":61,"en":62},"حساسیت به بیماتوپروست.","Hypersensitivity to bimatoprost.",[64],{"source":31,"section":65},"4",[67],{"text":68,"refs":71},{"fa":69,"en":70},"افزایش رنگدانه عنبیه (دائمی)، پلک و تغییر مژه؛ التهاب داخل چشم؛ ادم ماکولا.","Increased iris (permanent), eyelid pigmentation and eyelash changes; intraocular inflammation; macular oedema.",[72],{"source":31,"section":73},"5",[],[],[],{"status":78,"reviewer":79,"date":79},"unverified",null,[81],{"regimen":35,"formulation":22,"input":82,"expect":85},{"ageYears":83,"weightKg":84},60,70,{"perDose":5},[87],"S01EE03",{"status":89,"forms":90,"refs":111},"registered",[91,95,99,103,107],{"code":92,"en":93,"fa":94},"17537","BIMATOPROST 0.03% OPH GEL","ژل بیماتوپروست ۰٫۰۳ درصد",{"code":96,"en":97,"fa":98},"08581","BIMATOPROST 0.3MG\u002FML 3ML OPH DROP","قطره چشمی بیماتوپروست ۰٫۳ میلی‌گرم \u002F میلی‌لیتر ۳ میلی‌لیتر",{"code":100,"en":101,"fa":102},"52082","BIMATOPROST SOLUTION, DROPS OPHTHALMIC 0.03 % 3 mL","قطره چشمی بیماتوپروست ۰٫۰۳ درصد ۳ میلی‌لیتر",{"code":104,"en":105,"fa":106},"52781","BIMATOPROST SOLUTION, DROPS OPHTHALMIC 0.01 % 0.5 mL","قطره چشمی بیماتوپروست ۰٫۰۱ درصد ۰٫۵ میلی‌لیتر",{"code":108,"en":109,"fa":110},"52782","BIMATOPROST SOLUTION, DROPS OPHTHALMIC 0.03 % 0.5 mL","قطره چشمی بیماتوپروست ۰٫۰۳ درصد ۰٫۵ میلی‌لیتر",[112],{"source":113,"section":114,"url":115},"darooyab-generic","G-3176\u002FBimatoprost","https:\u002F\u002Fwww.darooyab.ir\u002FG-3176\u002FBimatoprost",{"kind":117,"refs":118,"id":121},"NDA",[119],{"source":31,"section":120},"SPL approval \u002F marketing category","NDA022184",[123,126,130,134,137,140],{"kind":124,"url":125,"label":121},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022184",{"kind":127,"url":128,"label":129},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=a5e67c75-db88-4372-bb07-c8dd15c97631","FDA Lumigan 0.01%",{"kind":131,"url":132,"label":133},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa602030.html","Bimatoprost Ophthalmic",{"kind":131,"url":135,"label":136},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa609009.html","Bimatoprost Topical",{"kind":138,"url":139,"label":87},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=S01EE03",{"kind":141,"url":115,"label":8},"darooyab",{"pregnancy":143,"pediatric":152,"geriatric":160},{"level":144,"text":145,"quote":148,"refs":149},"caution",{"fa":146,"en":147},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate and well-controlled studies of LUMIGAN ® (bimatoprost ophthalmic solution) 0.01% administration in pregnant women.",[150],{"source":31,"section":151},"8.1",{"level":144,"text":153,"quote":156,"refs":157},{"fa":154,"en":155},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.",[158],{"source":31,"section":159},"8.4",{"level":144,"text":161,"quote":164,"refs":165},{"fa":162,"en":163},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.",[166],{"source":31,"section":167},"8.5",1792191528931]